Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi‐ethnic cohort
Journal of Viral Hepatitis · 2024
DOI: 10.1111/jvh.13893 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Lung-Yi Mak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Institute for Health and Care Research (NIHR) under its Research for Patient Benefit (RfPB) Programme.
Abstract (Originalsprache)
Pregnant mothers with chronic hepatitis B infection (CHB) need peri‐partum antiviral prophylaxis (PAP) to reduce the risk of mother‐to‐child‐transmission. Currently, PAP is recommended in those with high viral load (VL) that is, HBV DNA >200,000 IU/mL. Quantitative hepatitis B surface antigen (qHBsAg) >10,000 IU/mL, a cut‐off derived primarily from hepatitis B e‐antigen (HBeAg) positive antenatal cohorts in Chinese populations, is advocated as a surrogate marker of VL for guiding PAP. We investigated the utility of qHBsAg to predict high‐VL in a multi‐ethnic urban cohort with CHB. A consecutive cohort of women with CHB was identified from Barts Health NHS Trust databases in the United Kingdom. We included women with paired HBV DNA and qHBsAg during pregnancy. Women already on antiviral at conception were excluded. A total of 769 pregnancies in 678 CHB pregnant mothers (median age 31 years‐old, 8.6% HBeAg+) were included. At median gestational age of 15.3 weeks, HBV DNA was 336 (IQR 44–2998) IU/mL, with 65 (8.5%) being high‐VL. Serum qHBsAg was most useful in Black/Black‐British/Caribbean/African (AUROC 0.946) with 100% sensitivity and 80.6% specificity to predict high‐VL; but it performed less well for other ethnicities: Asian (AUROC 0.877), White (AUROC 0.797) and mixed ethnicities (AUROC 0.742). In conclusion, for settings where healthcare resources are not limited, HBV DNA remains the optimal marker to identify highly viraemic pregnancies for guiding PAP. For resource‐limited settings where the prevailing cost is treatment, serum qHBsAg can be used in Black/Black British/Caribbean/African sub‐cohorts, but not for other ethnicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
- Virology Department, Division of Infection, Barts Health NHS Trust, London, UK.
ORCID-Profile: Lung-Yi Mak, Apostolos Koffas, Upkar Gill, Patrick T F Kennedy
Förderung
- The National Institute for Health and Care Research (NIHR) under its Research for Patient Benefit (RfPB) Programme
Zitieren
APA
Mak, L. Y., Koffas, A., Dolman, G. E., Saleh, H., Kemos, P., Riddell, A., Gill, U., & Kennedy, P. T. F. (2024). Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi‐ethnic cohort. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13893
Vancouver
Mak LY, Koffas A, Dolman GE, Saleh H, Kemos P, Riddell A, et al. Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi‐ethnic cohort. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13893
BibTeX
@article{Mak2024,
author = {Mak, Lung-Yi and Koffas, Apostolos and Dolman, Grace E and Saleh, Hossam and Kemos, Polychronis and Riddell, Anna and Gill, Upkar and Kennedy, Patrick T F},
title = {Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi‐ethnic cohort},
journal = {Journal of Viral Hepatitis},
year = {2024},
doi = {10.1111/jvh.13893}
}
EUVIMED